Amoy Diagnostics Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Amoy Diagnostics de 19.6% y 20.4% por año respectivamente. Se prevé que el BPA crezca en un 19.7% al año. Se espera que la rentabilidad financiera sea de 17.8% en 3 años.

Información clave

19.6%

Tasa de crecimiento de los beneficios

19.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	43.1%
Tasa de crecimiento de los ingresos	20.4%
Rentabilidad financiera futura	17.8%
Cobertura de analistas	Good
Última actualización	31 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24

Recent updates

Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Sep 18

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Aug 23

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

May 27

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Apr 18

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Mar 02

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Mar 01

Previsiones de crecimiento de beneficios e ingresos

SZSE:300685 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,861	477	349	396	9
12/31/2025	1,545	389	302	297	10
12/31/2024	1,266	318	253	236	7
9/30/2024	1,184	315	289	324	N/A
6/30/2024	1,128	279	262	295	N/A
3/31/2024	1,082	268	274	312	N/A
12/31/2023	1,044	261	254	299	N/A
9/30/2023	951	213	222	269	N/A
6/30/2023	908	301	164	222	N/A
3/31/2023	831	267	108	189	N/A
1/1/2023	842	264	71	149	N/A
9/30/2022	871	287	75	140	N/A
6/30/2022	911	218	81	146	N/A
3/31/2022	949	250	88	134	N/A
1/1/2022	917	240	94	168	N/A
9/30/2021	890	231	107	196	N/A
6/30/2021	844	211	125	224	N/A
3/31/2021	811	198	143	235	N/A
12/31/2020	728	180	163	221	N/A
9/30/2020	650	153	114	167	N/A
6/30/2020	595	138	126	159	N/A
3/31/2020	550	129	143	170	N/A
12/31/2019	578	135	128	152	N/A
9/30/2019	541	140	126	153	N/A
6/30/2019	502	135	87	120	N/A
3/31/2019	469	134	66	104	N/A
12/31/2018	439	127	54	93	N/A
9/30/2018	398	122	71	108	N/A
6/30/2018	384	120	N/A	114	N/A
3/31/2018	357	103	N/A	96	N/A
12/31/2017	330	94	N/A	92	N/A
9/30/2017	315	82	N/A	70	N/A
6/30/2017	288	78	N/A	49	N/A
3/31/2017	258	67	N/A	40	N/A
12/31/2016	253	67	N/A	32	N/A
6/30/2016	220	42	N/A	24	N/A
3/31/2016	198	32	N/A	22	N/A
12/31/2015	177	21	N/A	19	N/A
12/31/2014	107	19	N/A	16	N/A
12/31/2013	74	22	N/A	9	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (19.6% al año) de 300685 es superior a la tasa de ahorro (2.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (19.6% al año) de 300685 crezcan menos que el mercado CN (26.2% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 300685 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (20.4% al año) de 300685 crezcan más rápidamente que los del mercado CN (13.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (20.4% al año) de 300685 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 300685 sea baja dentro de 3 años (17.8%).

Amoy Diagnostics Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.0% to CN¥28.92

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Price target decreased by 7.6% to CN¥29.52

Price target decreased to CN¥35.47

Consensus revenue estimates fall by 18%

Price target decreased to CN¥41.29

Recent updates

Price target increased by 7.0% to CN¥28.92

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024

Investor sentiment improves as stock rises 35%

Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Now 20% undervalued

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent Director

Now 20% undervalued after recent price drop

Second quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Now 20% undervalued after recent price drop

Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

Dividend increased to CN¥0.15

Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Full year 2023 earnings: EPS exceeds analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024

Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.

Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Price target decreased by 7.6% to CN¥29.52

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Now 24% overvalued

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥35.47

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Price target decreased to CN¥41.29

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022

Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022

Amoy Diagnostics Co., Ltd. Approves Dividend for 2021

Price target decreased to CN¥82.96

High number of new directors

Amoy Diagnostics Co., Ltd. Announces the Profit Distribution Proposal for 2021

Price target decreased to CN¥93.33

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 15%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.

Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Limited Announces the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan

Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)

Price target increased to CN¥105

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. Announce the Approval of AmoyDx Pan Lung Cancer PCR Panel

Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)

New 90-day low: CN¥67.96

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2020 Results on Apr 13, 2021

New 90-day high: CN¥92.11

New 90-day high: CN¥87.26

New 90-day low: CN¥71.91

New 90-day low: CN¥72.29

Third quarter earnings released

New 90-day high - CN¥88.26